Active recall · Unapproved ingredientUpdated · 9 months ago
Anthony Trinh, 123Herbals LLC recall: Dietary supplement capsules marketed for relief of joint and body aches
FOR IMMEDIATE RELEASE – Date 01/07/2026 – Rosemead, CA, ANTHONY TRINH, 123herbals LLC is voluntarily recalling all lots of Silintan capsules to the consumer level. FDA analysis has found the product to be tainted with meloxicam. Meloxicam, is an approved Nonsteroidal Anti-Inflammatory Drug, (NSAID) indicated for management of osteoarthritis pain. Products containing meloxicam cannot be marketed as dietary supplements. The presence of Meloxicam in Silintan capsules, renders it an unapproved new drug for which the safety and efficacy have not been established and, therefore, subject to recall.
What to do
Anthony Trinh, 123Herbals LLC is notifying its distributors and customers by emails and is arranging for returns of all recalled products. Consumers and retailers that have Silintan capsules, which is being recalled, should stop using this product and/or return to the place of purchase, discard, or contact their doctor. Consumers with questions regarding this recall can contact Anthony Trinh, 123Herbals LLC by email at hello@123herbals.com or via phone at 1-626-656-3202, Monday - Friday 8am-5pm Pacific Time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. Customers can return their product to the point of purchase for a refund. Customers that bought from the website 123Herbals.com can return to 300 West Valley Blvd. P.O. Box 1925, Alhambra CA 91803.
Read the official notice, opens in a new tabHave one at home?
Check your pack’s codes and dates against this recall.
Which products
Dietary supplement capsules marketed for relief of joint and body aches
- Dates on pack
- Affected product information: this FDA announcement lists multiple products.
Anthony Trinh, 123Herbals LLC
Silintan
More detail
Unapproved new drug found to contain undeclared meloxicam
In the news
Reporting from news publishers. Follow the official notice for product advice.
No news stories about this recall yet.